ACT Wealth Management LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,830 shares of the company’s stock after selling 68 shares during the quarter. Johnson & Johnson accounts for approximately 0.2% of ACT Wealth Management LLC’s investment portfolio, making the stock its 21st biggest position. ACT Wealth Management LLC’s holdings in Johnson & Johnson were worth $325,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Magnolia Capital Management Ltd. increased its position in Johnson & Johnson by 0.5% in the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock valued at $1,978,000 after acquiring an additional 55 shares during the period. Howard Financial Services LTD. boosted its stake in Johnson & Johnson by 2.1% during the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock valued at $489,000 after purchasing an additional 57 shares in the last quarter. American Financial Advisors LLC boosted its stake in Johnson & Johnson by 2.1% during the 1st quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock valued at $481,000 after purchasing an additional 57 shares in the last quarter. Taylor & Morgan Wealth Management LLC boosted its stake in Johnson & Johnson by 1.6% during the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 3,580 shares of the company’s stock valued at $635,000 after purchasing an additional 57 shares in the last quarter. Finally, Kwmg LLC boosted its stake in Johnson & Johnson by 2.6% during the 1st quarter. Kwmg LLC now owns 2,354 shares of the company’s stock valued at $417,000 after purchasing an additional 59 shares in the last quarter. 68.59% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Stock Performance
Shares of Johnson & Johnson stock opened at $167.60 on Monday. The stock has a market cap of $440.65 billion, a PE ratio of 24.40, a price-to-earnings-growth ratio of 2.99 and a beta of 0.61. The business has a fifty day simple moving average of $168.96 and a 200-day simple moving average of $174.29. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter last year, the firm posted $2.48 earnings per share. Johnson & Johnson’s revenue was up 3.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.7 EPS for the current fiscal year.
Johnson & Johnson announced that its Board of Directors has initiated a stock buyback program on Wednesday, September 14th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to purchase up to 1.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its shares are undervalued.
Johnson & Johnson Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were issued a dividend of $1.13 per share. The ex-dividend date of this dividend was Monday, August 22nd. This represents a $4.52 annualized dividend and a dividend yield of 2.70%. Johnson & Johnson’s dividend payout ratio is 65.79%.
Analysts Set New Price Targets
A number of equities analysts have issued reports on JNJ shares. Daiwa Capital Markets started coverage on Johnson & Johnson in a research note on Wednesday, June 22nd. They set an “outperform” rating for the company. Morgan Stanley decreased their price target on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating for the company in a research note on Monday, September 12th. UBS Group reduced their price objective on Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Citigroup reduced their price objective on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Finally, SVB Leerink reduced their price objective on Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $189.78.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Recommended Stories
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
